Parenteral high‑dose ascorbate - A possible approach for the treatment of glioblastoma (Review).

摘要: For glioblastoma, the treatment with standard of care therapy comprising resection, radiation, and temozolomide results in overall survival approximately 14-18 months after initial diagnosis. Even though several new approaches are under investigation, it is difficult to achieve life prolongation and/or improvement patient's quality life. The aggressiveness progression glioblastoma initially orchestrated by biological complexity its genetic phenotype ability respond cancer via changing molecular patterns, thereby developing resistance. Recent clinical studies pharmacological ascorbate have demonstrated safety potential efficacy different entities regarding survival. In this review article, actual possibilities summarized, evidence for examined questions posed identify current gaps knowledge accessibility tumor area. Experiments cell lines xenografts that high‑dose induces cytotoxicity oxidative stress largely selectively malignant cells compared normal suggesting as a therapeutic agent. Further investigations larger cohorts randomized placebo‑controlled trials should be performed confirm these findings well improve delivery strategies brain, through inherent barriers ultimately cells.